Improved clinical outcomes in patients treated with natalizumab for at least 8 years - real-world data from a Swedish national post-marketing surveillance study (IMSE 1)

S. Kågström, A. Fält,L. Forsberg,A. Berglund,J. Hillert,P. Nilsson,C. Dahle,A. Svenningsson,J. Lycke,A. M Landtblom,J. Burman,P. Sundström,C. Martin,Martin Gunnarsson,F. Piehl,T. Olsson

MULTIPLE SCLEROSIS JOURNAL（2019）

引用 0|浏览27

暂无评分

摘要

Background: Natalizumab (NTZ) is a highly effective disease modulatory treatment for relapsing-remitting multiple sclerosis (RRMS). Post-marketing surveillance is important for evaluation of long-t ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要